A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLL

The CLL-Frail2 trial will be a prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a fitness-adapted therapy approach with either con-tinuous zanubrutinib (BGB-3111) monotherapy or time-limited zanubrutinib + sonrotoclax (BGB-11417) in older (aged ≥80 years) and/or frail patients with treatment-naïve CLL. The primary objective of the study is to evaluate the efficacy and safety of fitness-adapted therapy in older (aged ≥80 years) and/or frail patients with treatment-naïve CLL.